Tickers

1. Composite Trajectory Verdict

The income statement matters most for assessing MOH's financial performance because its managed-care model is fundamentally a spread business where profitability hinges on the difference between premium revenue and medical costs, and the filings show that spread compressing sharply across all segments.

Composite Trajectory: Deteriorating

The earnings trajectory is the primary driver: consolidated net income fell 60% year-over-year in FY 2025 ($472M vs $1,179M) and 76% in Q2 2026 ($60M vs $255M), with the medical care ratio rising 260 bps annually and 180 bps quarterly. Cash flow provides a partial offset — year-to-date operating cash flow improved to $788M in H1 2026 from -$112M in H1 2025 — but the filing attributes this to timing of government settlements rather than operating improvement. The balance sheet shows higher leverage (long-term debt up 29% to $3.8B) and lower equity ($4.1B vs $4.5B at end-2024), though cash recovered to $9.2B at June 2026 from $8.6B at year-end 2025.

2. Red Flags

• Severe margin compression across all segments: Consolidated MCR rose from 89.1% (FY 2024) to 91.7% (FY 2025) and from 90.4% (Q2 2025) to 92.2% (Q2 2026) (10-K FY 2025, Financial Results Summary; 10-Q Q2 2026, Consolidated Financial Summary). Marketplace MCR jumped from 75.4% to 90.6% annually (+1,520 bps) (10-K FY 2025, Segment Financial Performance).
• Profit collapse: Operating income fell 54% annually ($781M vs $1,707M) and 61% quarterly ($145M vs $373M); net income fell 60% annually and 76% quarterly (10-K FY 2025, Consolidated Statements of Operations; 10-Q Q2 2026, Consolidated Statements of Operations).
• Operating cash flow turned negative in FY 2025: -$535M vs +$644M in FY 2024, a $1.18B swing (10-K FY 2025, Consolidated Statements of Cash Flows).
• Membership decline accelerating: Total membership fell from 5.7M (June 2025) to 4.9M (June 2026), a 14% drop in 12 months, with Marketplace down 59% (690K to 283K) and Medicaid down 7% (4.77M to 4.42M) (10-Q Q2 2026, Segment Membership).
• Debt rating downgrade and covenant relief: S&P lowered senior notes to BB- from BB in April 2026; Credit Agreement amended February 2026 to temporarily reduce Interest Coverage Ratio threshold from 3.0x to 1.75x through December 2026 (10-Q Q2 2026, Debt Ratings; 10-Q Q2 2026, Financial Covenants).
• $93M impairment charge in Q1 2026 for planned MAPD exit (10-Q Q2 2026, Consolidated Statements of Operations; Impairment note).
• Securities class action and derivative suit filed in October and December 2025 alleging misleading disclosures (10-K FY 2025, Legal Proceedings).
• Pre-tax margin compression: 3.9% (FY 2024) to 1.3% (FY 2025); 2.8% (Q2 2025) to 0.8% (Q2 2026) (10-K FY 2025, Financial Results Summary; 10-Q Q2 2026, Consolidated Financial Summary).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Revenue grew 12% annually to $45.4B in FY 2025 driven by the ConnectiCare acquisition, Medicaid rate increases, and Marketplace membership growth, but medical costs rose 15% to $39.5B, pushing the consolidated MCR to 91.7% from 89.1% (10-K FY 2025, Consolidated Statements of Operations). All three major segments saw MCR increases: Medicaid +150 bps to 91.8%, Medicare +330 bps to 92.4%, Marketplace +1,520 bps to 90.6% (10-K FY 2025, Segment Financial Performance). In Q2 2026, premium revenue declined 6% to $10.2B while MCR rose to 92.2%, driving medical margin down 23% to $804M; operating income fell 61% to $145M and net income 76% to $60M (10-Q Q2 2026, Consolidated Financial Summary). The G&A ratio improved slightly annually (6.6% vs 6.7%) but worsened quarterly (6.7% vs 6.2%) due to lower revenue (10-K FY 2025; 10-Q Q2 2026). Interest expense rose 63% annually to $192M and 13% quarterly to $54M from new debt issuances (10-K FY 2025; 10-Q Q2 2026).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Full-year 2025 operating cash flow swung to -$535M from +$644M in 2024, a $1.18B deterioration attributed to lower operating income, timing of government settlements, and tax payments (10-K FY 2025, Consolidated Statements of Cash Flows). However, year-to-date June 2026 operating cash flow rebounded to +$788M from -$112M in the prior-year period, which the filing attributes to favorable timing of Medicaid minimum MLR, medical cost corridor, and Marketplace risk adjustment settlements, partially offset by lower net income (10-Q Q2 2026, Operating Activities). Investing cash flow shifted from -$464M in FY 2024 to +$312M in FY 2025 due to net investment proceeds of $657M vs $21M of purchases in 2024 (10-K FY 2025, Investing Activities). Financing cash flow was -$170M in FY 2025 and -$24M in H1 2026, with $1B of share repurchases in each period (10-K FY 2025; 10-Q Q2 2026, Financing Activities). Total cash and investments rose to $9.2B at June 2026 from $8.6B at December 2025 after falling from $9.3B at December 2024 (10-Q Q2 2026, Financial Condition; 10-K FY 2025, Financial Condition).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Total assets were roughly flat annually ($15.6B at December 2025 vs $15.6B at December 2024) but rose 3% to $16.0B at June 2026 (10-K FY 2025, Consolidated Balance Sheets; 10-Q Q2 2026, Consolidated Balance Sheets). Long-term debt increased 29% to $3.8B at December 2025 from $2.9B at December 2024 following $850M of 6.500% notes issued in November 2025, and remained at $3.8B at June 2026 (10-K FY 2025, Debt; 10-Q Q2 2026, Consolidated Balance Sheets). Stockholders' equity declined 9% to $4.1B at December 2025 from $4.5B at December 2024 due to $1B of share repurchases and lower retained earnings, then recovered modestly to $4.2B at June 2026 (10-K FY 2025, Consolidated Statements of Stockholders' Equity; 10-Q Q2 2026, Consolidated Balance Sheets). Medical claims payable rose 5% to $4.9B at December 2025 from $4.6B, then dipped slightly to $4.8B at June 2026 (10-K FY 2025; 10-Q Q2 2026). Amounts due government agencies fell 29% to $1.3B at December 2025 from $1.9B, then rose 25% to $1.7B at June 2026 (10-K FY 2025; 10-Q Q2 2026). Parent company cash and investments were $223M at December 2025 vs $445M at December 2024, recovering to $290M at June 2026 (10-K FY 2025, Liquidity; 10-Q Q2 2026, Liquidity).

6. Data Gaps

• Quarterly income statement and cash flow data for Q3 2025, Q4 2025, and Q1 2026 (only Q2 2025, Q2 2026, and FY 2024/2025 annuals are provided)
• Segment-level cash flow statements
• Full-year 2026 results (only six months available)
• Detailed breakdown of "Amounts due government agencies" by program (Medicaid MLR, Medicare MLR, Marketplace risk adjustment) for quarterly periods
• Interest coverage ratio calculations under the Credit Agreement for each quarter
• Prior year development of medical claims by segment for quarterly periods beyond the six-month roll-forward